11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Heparan sulfate accumulation and perlecan/HSPG2 up-regulation in tumour tissue predict low relapse-free survival for patients with glioblastoma.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Glycosaminoglycans are major components of brain extracellular matrix (ECM), although heparan sulfate (HS) contribution in brain physiology and carcinogenesis remains underinvestigated. This study examined HS content and distribution in glioblastoma multiforme (GBM) tissues in the context of potential molecular mechanisms underlying its deregulation in brain tumours. Totally, 42 tissue samples and paraffin-embedded tissues for 31 patients with different prognosis were investigated. HS expression was demonstrated in 50-55% of the GBM tumours by immunohistochemistry (IHC), while almost no HS content was detected in the surrounding paratumourous brain tissues. Heterogeneous HS distribution in the HS-positive tumours was more related to the necrosis or glandular-like brain zones rather than glioma cells with high or low Ki-67 index. According the Kaplan-Meier curves, HS accumulation in glioma cells was associated with low relapse-free survival (RS) of the GBM patients (p < 0.05) and was likely to be due to the increased transcriptional activity of HSPG core proteins (syndecan-1, 2-3 fold; glypican-1, 2,5 fold; perlecan/HSPG2, 13-14 fold). Activation of perlecan/HSPG2 expression correlated with the patients' survival according Kaplan-Meier (p = 0.0243) and Cox proportional-hazards regression (HR = 3.1; P(Y) = 0.03) analyses, while up-regulation of syndecan-1 and glypican-1 was not associated with the patients survival. Taken together, the results indicate that increase of HS content and up-regulation of perlecan/HSPG2 expression in glioblastoma tissues contribute to tumour development through the transformation of brain extracellular matrix into tumour microenvironment, and represent negative prognostic factors for glioblastoma progression.

          Related collections

          Author and article information

          Journal
          Histochem. Cell Biol.
          Histochemistry and cell biology
          Springer Nature America, Inc
          1432-119X
          0948-6143
          Mar 2018
          : 149
          : 3
          Affiliations
          [1 ] Institute of Molecular Biology and Biophysics, Timakova 2/12, Novosibirsk, 630117, Russia.
          [2 ] Meshalkin National Medical Research Center, Novosibirsk, Russia.
          [3 ] Novosibirsk State Medical University, Novosibirsk, Russia.
          [4 ] Novosibirsk State University, Novosibirsk, Russia.
          [5 ] European Medical Centre, Moscow, Russia.
          [6 ] Institute of Molecular Biology and Biophysics, Timakova 2/12, Novosibirsk, 630117, Russia. elv_grig@yahoo.com.
          [7 ] Meshalkin National Medical Research Center, Novosibirsk, Russia. elv_grig@yahoo.com.
          [8 ] Novosibirsk State University, Novosibirsk, Russia. elv_grig@yahoo.com.
          Article
          10.1007/s00418-018-1631-7
          10.1007/s00418-018-1631-7
          29322326
          6be18bbc-451d-4bbe-a42a-9a1003205fcc
          History

          Proteoglycan,Glioblastoma,Glypican-1,Heparan sulfate,Perlecan/HSPG2,Syndecan-1

          Comments

          Comment on this article